poisar

Stocks · News reference

Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate

Benzinga Newsdesk

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.47) by 12.77 percent. This is a 55.88 percent decrease over losses of $(0.34) per

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

EWTX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?

    Bristol Myers Squibb's Camzyos demonstrated durable reductions in LVOT obstruction over five years with 97.4% of patients achieving target gradients. Sales surged 74% year-over-year to $729 million in H1 2026. The company seeks FDA approval for adolescents with a decision expected by September 30, 2026. However, competition is intensifying with Cytokinetics' Myqorzo approved in December 2025 and Edgewise Therapeutics advancing EDG-7500 in clinical trials.

    BMYCELGRCYTKEWTX
  2. Na

    Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

    Cytokinetics announced additional positive results from ACACIA-HCM and MAPLE-HCM studies showing aficamten improved cardiac structure and diastolic function in non-obstructive HCM patients, and outperformed metoprolol in obstructive HCM. The company plans to file for nHCM approval in Q4 2026, potentially expanding the drug's addressable market. Myqorzo received FDA approval in December 2025 for obstructive HCM treatment.

    CYTKBMYCELGREWTX